US Stock Futures Down Ahead Of Economic Data

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Pre-open moversUS stock futures traded lower in early pre-market trade. Data on consumer spending for August will be released at 8:30 a.m. ET, while the pending home sales index for August will be released at 10:00 a.m. ET. The Dallas Fed general business activity index for September will be released at 10:30 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 69 points to 16,961.00, while the Standard & Poor's 500 index futures fell 7.80 points to 1,968.10. Futures for the Nasdaq 100 index dropped 16.25 points to 4,029.50.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were lower today, with the Spanish Ibex Index dropping 0.86%, STOXX Europe 600 Index falling 0.26%. German DAX 30 index declined 0.23%, French CAC 40 Index slipped 0.33% and London's FTSE 100 Index dropped 0.23%.In Asian markets, Japan's Nikkei Stock Average surged 0.50%, Hong Kong's Hang Seng Index fell 1.90%, China's Shanghai Composite Index rose 0.43% and India's BSE Sensex dropped 0.11%.Broker Recommendation

Analysts at Credit Suisse upgraded Nike (NYSE: NKE) from Neutral to Outperform. The target price for Nike has been raised from $80 to $100. Nike's shares dropped 0.45% to $89.10 in pre-market trading. Breaking news

AMAG Pharmaceuticals (NASDAQ: AMAG) today announced that it has entered into a definitive agreement to acquire Lumara Health Inc., a privately-held pharmaceutical company specializing in women's health, for $675 million ($600 million in cash and $75 million in stock) and additional contingent consideration of up to $350 million based on achievement of certain sales milestones. To read the full news, click here.
Puma Biotechnology (NYSE: PBYI) announced that positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) with HER2 mutations was presented today as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain. To read the full news, click here.
Encana Corporation (NYSE: ECA) and Athlon Energy (NYSE: ATHL) today jointly announced that the two companies have entered into a definitive merger agreement for Encana to acquire all of the issued and outstanding shares of common stock of Texas-based Athlon by means of an all-cash tender offer for US$5.93 billion (US$58.50 per share), as well as Encana assuming Athlon's US$1.15 billion of senior notes, for a total transaction value of approximately US$7.1 billion. To read the full news, click here.
Cal-Maine Foods (NASDAQ: CALM) reported a rise in its fiscal first-quarter earnings. To read the full news, click here.